+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hip Osteoarthritis Pain Drug Market - Global Forecast 2026-2032- Product Image
Hip Osteoarthritis Pain Drug Market - Global Forecast 2026-2032- Product Image
Sale

Hip Osteoarthritis Pain Drug Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6139349
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Hip Osteoarthritis Pain Drug Market is projected to reach USD 1.35 Billion in 2026. It is expected to continue growing at a CAGR of 5.30%, reaching USD 1.84 Billion by 2032.

Hip Osteoarthritis Pain Drug Market: Executive Summary

Hip osteoarthritis pain drugs address symptomatic pain and functional limitations associated with degenerative joint disease. Clinical decision-making generally balances analgesic benefit, tolerability, comorbidities, age, disease severity, and the potential need for nonpharmacological care or surgery. Treatment pathways commonly include topical or oral nonsteroidal anti-inflammatory drugs where appropriate, acetaminophen in selected patients, and carefully supervised alternatives when standard options are unsuitable. Regulatory status, prescribing guidance, and patient risk profiles differ across jurisdictions.

Treatment Is Shifting Toward Risk-Sensitive, Multimodal Care

The treatment landscape is moving away from one-size-fits-all pain control toward multimodal management that combines exercise, weight management, physical therapy, assistive devices, and medicines. Clinicians are placing greater emphasis on gastrointestinal, renal, cardiovascular, hepatic, and dependence-related risks, particularly for older adults with multiple conditions. Shared decision-making and periodic reassessment are increasingly important because symptom relief, functional improvement, and medication safety may not move together.

Artificial Intelligence Is Strengthening Clinical Support and Evidence Generation

Artificial intelligence can support this field through evidence synthesis, patient stratification, adverse-event signal detection, imaging interpretation, and adherence monitoring. Predictive tools may help identify patients at higher risk of medication-related complications or rapid functional decline, while natural-language systems can assist with clinical documentation and guideline retrieval. These applications require representative data, prospective validation, transparent performance reporting, privacy safeguards, and clinician oversight; they should support rather than replace individualized prescribing decisions.

Regional Insights: Access and Clinical Practice Reflect Local Health Systems

In North America, treatment is shaped by structured clinical guidance, strong attention to opioid stewardship, and broad use of nonpharmacological interventions, although affordability and insurance coverage can affect access. Europe combines evidence-based prescribing with differing national reimbursement rules and regulatory practices across countries. Asia-Pacific includes highly diverse health systems, aging populations, and varying access to specialist care and newer formulations. Latin America faces uneven medicine availability and healthcare access, while the Middle East includes substantial variation between well-resourced and capacity-constrained systems. Africa commonly encounters barriers involving diagnosis, supply continuity, affordability, and specialist availability, making primary-care integration and appropriate use especially important.

Group Insights: Economic and Security Blocs Have Uneven Priorities

ASEAN markets reflect diverse regulatory systems, income levels, and healthcare capacities, creating different pathways for medicine registration and access. BRICS countries span major differences in public procurement, domestic manufacturing, and treatment affordability. The European Union benefits from shared scientific and regulatory frameworks but retains national variation in reimbursement and prescribing implementation. G7 systems generally emphasize safety monitoring, evidence standards, and coordinated chronic-disease management. GCC countries often combine modern tertiary facilities with varying levels of local capacity and imported-medicine dependence. NATO members are not a uniform healthcare bloc, but many share priorities around resilient supply chains, emergency preparedness, and continuity of essential care.

Country Insights: National Guidance, Access, and Demographics Shape Use

Australia and Canada emphasize primary-care coordination and guideline-based risk assessment, with geography influencing specialist access. Brazil, Mexico, India, and Russia face substantial regional variation in affordability, availability, and care delivery. China is balancing an aging population with evolving reimbursement, procurement, and clinical-standardization efforts. Japan and South Korea have mature health systems and aging populations, supporting detailed monitoring of medication safety and function. France, Germany, Italy, Spain, and the United Kingdom operate within established European regulatory environments, while reimbursement rules and referral pathways differ nationally. The United States has extensive clinical options and research activity, alongside pronounced variation in coverage, prescribing patterns, and access.

Recommendations for Leaders: Improve Safety, Access, and Evidence Quality

Industry leaders should prioritize products and services with clearly defined clinical value, transparent safety information, and practical dosing guidance for older adults and patients with comorbidities. Evidence programs should measure pain, mobility, quality of life, treatment persistence, and adverse events rather than relying solely on short-term symptom scores. Partnerships with clinicians, payers, pharmacists, and patient groups can improve appropriate use and adherence. Regional strategies should account for registration requirements, procurement structures, affordability constraints, supply resilience, and culturally appropriate patient education. Digital and AI-enabled tools should be introduced through governed pilots with human review and measurable clinical outcomes.

Research Methodology: Evidence-Based Synthesis of Treatment and System Factors

This executive summary uses a structured qualitative approach focused on the hip osteoarthritis pain drug treatment context. The analysis considers established clinical-management principles, medicine safety considerations, health-system access, regulatory diversity, demographic trends, and the potential role of artificial intelligence. Regional, group, and country observations are framed as comparative system insights rather than quantitative market claims. Conclusions should be validated against current peer-reviewed evidence, clinical guidelines, regulatory communications, reimbursement policies, and local prescribing data before operational decisions are made.

Conclusion: Responsible Innovation Should Center on Function and Patient Safety

The hip osteoarthritis pain drug landscape is defined by an aging and clinically diverse patient population, persistent need for symptom relief, and growing scrutiny of medicine-related risks. The strongest pathway forward combines individualized pharmacological treatment with rehabilitation and other non-drug measures, supported by reliable access and follow-up. Artificial intelligence can improve evidence generation and care coordination when deployed transparently and validated clinically. Leaders who align innovation with safety, affordability, regional realities, and functional outcomes will be better positioned to support appropriate long-term care.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Hip Osteoarthritis Pain Drug Market, by Mechanism Of Action
7.1. Introduction
7.2. Corticosteroids
7.3. Hyaluronic Acid
7.4. Nonsteroidal Anti-Inflammatory Drugs
7.5. Opioids
7.6. Serotonin Norepinephrine Reuptake Inhibitors
8. Hip Osteoarthritis Pain Drug Market, by Route Of Administration
8.1. Introduction
8.2. Injectable
8.3. Oral
8.4. Topical
8.5. Transdermal
9. Hip Osteoarthritis Pain Drug Market, by Patient Age Group
9.1. Introduction
9.2. Adult
9.3. Pediatrics
9.4. Geriatrics
10. Hip Osteoarthritis Pain Drug Market, by End User
10.1. Introduction
10.2. Ambulatory Care Centers
10.3. Home Care Settings
10.4. Hospital Pharmacies
10.5. Specialty Clinics
11. Hip Osteoarthritis Pain Drug Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Hip Osteoarthritis Pain Drug Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Hip Osteoarthritis Pain Drug Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abbott Laboratories
15.2. AbbVie Inc.
15.3. Amgen Inc.
15.4. Anika Therapeutics, Inc.
15.5. Bayer AG
15.6. Bioventus LLC
15.7. Eli Lilly and Company
15.8. Flexion Therapeutics, Inc.
15.9. GlaxoSmithKline plc
15.10. Janssen Pharmaceutica NV
15.11. Johnson & Johnson
15.12. Merck & Co., Inc.
15.13. Merck Sharp & Dohme Corp. (MSD)
15.14. Novartis AG
15.15. Pacira Pharmaceuticals, Inc.
15.16. Pfizer Inc.
15.17. Regeneron Pharmaceuticals, Inc.
15.18. Sanofi S.A.
15.19. Takeda Pharmaceutical Company Limited
15.20. Teva Pharmaceutical Industries Ltd.
15.21. Viatris Inc.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Hip Osteoarthritis Pain Drug Market, Years Considered for the Study
FIGURE 2. Global Hip Osteoarthritis Pain Drug Market, Research Design
FIGURE 3. Global Hip Osteoarthritis Pain Drug Market, Research Framework
FIGURE 4. Global Hip Osteoarthritis Pain Drug Market, Data Triangulation
FIGURE 5. Global Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 7. Global Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 11. Global Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Hip Osteoarthritis Pain Drug Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Hip Osteoarthritis Pain Drug Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Hip Osteoarthritis Pain Drug Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Hip Osteoarthritis Pain Drug Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Hip Osteoarthritis Pain Drug Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Hip Osteoarthritis Pain Drug Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Hip Osteoarthritis Pain Drug Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Hip Osteoarthritis Pain Drug Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Hip Osteoarthritis Pain Drug Market Segmentation & Coverage
TABLE 2. Global Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 3. Global Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 4. Global Corticosteroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Corticosteroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Corticosteroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Hyaluronic Acid Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Hyaluronic Acid Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Hyaluronic Acid Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Nonsteroidal Anti-Inflammatory Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Nonsteroidal Anti-Inflammatory Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Nonsteroidal Anti-Inflammatory Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Opioids Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Opioids Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Opioids Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Serotonin Norepinephrine Reuptake Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Serotonin Norepinephrine Reuptake Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Serotonin Norepinephrine Reuptake Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 20. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Topical Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Topical Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Topical Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Transdermal Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Transdermal Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Transdermal Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 33. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Pediatrics Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Pediatrics Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Pediatrics Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Geriatrics Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Geriatrics Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Geriatrics Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 43. Global Ambulatory Care Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Ambulatory Care Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Ambulatory Care Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Home Care Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Home Care Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Home Care Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Hip Osteoarthritis Pain Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Hip Osteoarthritis Pain Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 61. North America Hip Osteoarthritis Pain Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. North America Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 63. North America Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 64. North America Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 65. North America Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 66. Latin America Hip Osteoarthritis Pain Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Latin America Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 68. Latin America Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 69. Latin America Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 70. Latin America Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 71. Europe Hip Osteoarthritis Pain Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Europe Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 73. Europe Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 74. Europe Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 75. Europe Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 76. Middle East Hip Osteoarthritis Pain Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Middle East Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 78. Middle East Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 79. Middle East Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 80. Middle East Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. Africa Hip Osteoarthritis Pain Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Africa Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 83. Africa Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 84. Africa Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 85. Africa Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 86. Global Hip Osteoarthritis Pain Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. ASEAN Hip Osteoarthritis Pain Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. ASEAN Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 89. ASEAN Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 90. ASEAN Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 91. ASEAN Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 92. GCC Hip Osteoarthritis Pain Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. GCC Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 94. GCC Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 95. GCC Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 96. GCC Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 97. European Union Hip Osteoarthritis Pain Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. European Union Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 99. European Union Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 100. European Union Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 101. European Union Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. BRICS Hip Osteoarthritis Pain Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. BRICS Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 104. BRICS Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 105. BRICS Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 106. BRICS Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 107. G7 Hip Osteoarthritis Pain Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. G7 Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 109. G7 Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 110. G7 Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 111. G7 Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 112. NATO Hip Osteoarthritis Pain Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. NATO Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 114. NATO Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 115. NATO Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 116. NATO Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. Global Hip Osteoarthritis Pain Drug Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. United States Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 119. United States Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 120. United States Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 121. United States Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 122. United States Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 123. Canada Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 124. Canada Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 125. Canada Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 126. Canada Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 127. Canada Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. Mexico Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 129. Mexico Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 130. Mexico Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 131. Mexico Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 132. Mexico Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 133. Brazil Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 134. Brazil Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 135. Brazil Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 136. Brazil Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 137. Brazil Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. United Kingdom Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 139. United Kingdom Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 140. United Kingdom Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 141. United Kingdom Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 142. United Kingdom Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. Germany Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 144. Germany Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 145. Germany Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 146. Germany Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 147. Germany Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. France Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 149. France Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 150. France Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 151. France Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 152. France Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. Russia Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 154. Russia Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 155. Russia Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 156. Russia Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 157. Russia Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 158. Italy Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 159. Italy Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 160. Italy Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 161. Italy Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 162. Italy Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. Spain Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 164. Spain Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 165. Spain Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 166. Spain Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 167. Spain Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 168. China Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 169. China Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 170. China Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 171. China Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 172. China Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 173. India Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 174. India Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 175. India Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 176. India Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 177. India Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 178. Japan Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 179. Japan Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 180. Japan Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 181. Japan Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 182. Japan Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 183. Australia Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 184. Australia Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 185. Australia Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 186. Australia Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 187. Australia Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 188. South Korea Hip Osteoarthritis Pain Drug Market Size, 2017-2032 (USD Million)
TABLE 189. South Korea Hip Osteoarthritis Pain Drug Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 190. South Korea Hip Osteoarthritis Pain Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 191. South Korea Hip Osteoarthritis Pain Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 192. South Korea Hip Osteoarthritis Pain Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. Global Hip Osteoarthritis Pain Drug Market Share, by Key Player, 2025
TABLE 194. Global Hip Osteoarthritis Pain Drug Market, Key Experts

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Anika Therapeutics, Inc.
  • Bayer AG
  • Bioventus LLC
  • Eli Lilly and Company
  • Flexion Therapeutics, Inc.
  • GlaxoSmithKline plc
  • Janssen Pharmaceutica NV
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Merck Sharp & Dohme Corp. (MSD)
  • Novartis AG
  • Pacira Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Related Topics

Related Reports

Osteoarthritis Pain Drug Market - Global Forecast 2026-2032 - Product Image

Osteoarthritis Pain Drug Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Neuropathic Pain Drug Market - Global Forecast 2026-2032 - Product Image

Neuropathic Pain Drug Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Post Surgical Pain Drug Pipeline Analysis Report 2026 - Product Image

Post Surgical Pain Drug Pipeline Analysis Report 2026

  • Drug Pipelines
  • 150 Pages
  • Global
From
Osteoarthritis Therapeutics - Global Strategic Business Report - Product Image

Osteoarthritis Therapeutics - Global Strategic Business Report

  • Report
  • 266 Pages
  • Global
From
Osteoarthritis - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Osteoarthritis - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 289 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.